<DOC>
	<DOCNO>NCT00005853</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Combining different type biological therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness biological therapy treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Biological Therapy Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine frequency hematologic response patient myelodysplastic syndrome treat anti-thymocyte globulin tumor necrosis factor receptor IgG chimera . - Correlate phenotypic , cytogenetic , functional disease characteristic treatment responses patient . - Determine safety treatment regimen patient population . OUTLINE : Patients receive anti-thymocyte globulin IV 8 hour daily 4 day follow tumor necrosis factor receptor IgG chimera subcutaneously twice weekly 16 week . Patients follow 8 , 16 , 20 week . PROJECTED ACCRUAL : A total 15 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis myelodysplastic syndrome great 20 % marrow blast : Single multilineage cytopenia ( neutrophils less 2,000/mm^3 and/or platelet count le 100,000/mm^3 and/or reticulocyte count le 18,000/mm^3 ) OR Transfusion requirement least 2 unit pack red blood cell per month one following : Suitable marrow donor unavailable Ineligible transplantation protocol Unwilling proceed transplantation No chronic myelomonocytic leukemia PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : No severe disease would preclude study No active severe infection ( e.g. , pneumonia septicemia ) severe infection within past 2 week PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior hematopoietic growth factor No concurrent hematopoietic growth factor Chemotherapy : At least 4 week since prior cytotoxic therapy No concurrent cytotoxic therapy Endocrine therapy : Not specify Radiation therapy : Not specify Surgery : Not specify Other : At least 4 week since prior immunomodulatory therapy No concurrent immunomodulatory therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>